Abstract. Twenty hyperthyroid patients were randomly assigned in a double-blind fashion to receive either nadolol 80 mg/day or placebo for 2 weeks; all patients then took carbimazole as well from 2\p=n-\6 weeks. Twenty-four hour Holter ECG recordings at 0, 2 and 6 weeks showed that nadolol reduced the mean maximum heart rate by 19.9% (P < 0.0005) at 2 weeks and by 30.3% (P < 0.0005) at 6 weeks compared to 5.2% (ns) and 18.3% (P < 0.0005) in patients taking placebo.
There was no alteration of the normal circadian variation of heart rate by nadolol. The minimum heart rate before therapy was significantly correlated with FT4 (r = 0.52) and with FT3 (r = 0.44). The percentage of time per hour during which the heart rate was greater than 100 was reduced by 79% at week 2 by nadolol compared to 22% in the placebo group. At the 6 week point the placebo group still had a tachycardia (mean maximum heart rate 101.6 beats/min \m=+-\15.2 SD) compared to the nadolol group (80.4 \m=+-\ 7.7). Nadolol did not cause excessive bradycardia. It is effective in the early management of hyperthyroidism and should be given for at least the first 4\p=n-\6 weeks.
Tachycardia is one of the cardinal manifestations of hyperthyroidism, but there are few data re¬ garding the 24 h variation in heart rate in this disease and its response to beta-adrenoceptor blockade studied in detail. Jansson et al. (1984) recently studied 19 hyperthyroid patients by Hol- ter electrocardiography and showed a 20% reduc¬ tion in mean 24 h heart rate in patients rendered euthyroid but did not use ß-blockers. Forfar et al. (1982) 
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Mean maximum heart rates (± SD) in the two groups at 0, 2 and 6 weeks. correlation between these differences and the maximum heart rates (r = 0.88, < 0.001).
There was no significant difference before treatment in the mean maximum heart rate be¬ tween groups A and (Fig. 1) (Fig.   2) . Inspection of the maximum heart rates during the 24 h period in both groups at 0 and 2 weeks ( Fig. 1) (Morkin et al. 1983 ).
ß-adrenoreceptor blocking drugs are of proven efficacy in the reduction of heart rate in hyper¬ thyroidism (Utiger 1984; Feely & Peden 1984 
